| 货号 | AF781-SP |
| 别名 | IFG; IFI; IFNG; IFN-gamma; Immune interferon; interferon gamma; interferon, gamma | 全称 | Interferon gamma |
| 反应种属 | Canine |
| 应用 | Western Blot(0.1 µg/mL) Immunocytochemistry(5-15 µg/mL) |
| 目标/特异性 | Detects canine IFN-gamma in direct ELISAs and Western blots. In direct ELISAs, less than 40% cross-reactivity with recombinant porcine IFN‑ gamma is observed, approximately 20% cross-reactivity with recombinant feline IFN‑ gamma is observed, and less than 5% cross-reactivity with recombinant human IFN-gamma, recombinant rhesus macaque IFN-gamma, recombinant mouse IFN‑ gamma, and recombinant rat IFN‑ gamma is observed. |
| 使用方法 | Western Blot: 0.1 µg/mL Immunocytochemistry: 5-15 µg/mL Neutralization: Measured by its ability to neutralize IFN‑ gamma inhibition of VSV-induced cytopathy in the A‑72 canine fibroma cell line. The Neutralization Dose (ND50) is typically 0.2-1 µg/mL in the presence of 1.5 ng/mL Recombinant Canine IFN‑ gamma. |
| 来源 | Polyclonal Goat IgG |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 3458 (Human); 15978 (Mouse); 25712 (Rat); 396991 (Porcine); 281237 (Bovine); 403801 (Canine); 493965 (Feline) |
| 应用文献 | |
| R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. Impact of plasmid supercoiling on the efficacy of a rabies DNA vaccine to protect cats. | |
| 纯化方式 | Antigen Affinity-purified |
| 免疫原 | E. coli-derived recombinant canine IFN-gamma Gln24-Lys166 Accession # P42161 |
| 内毒素水平 | <0.10 EU per 1 μg of the antibody by the LAL method. |
| 生物活性 | Canine |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 背景 | Interferon-gamma (IFN-gamma ), also known as type II or immune interferon, exerts a wide range of immunoregulatory activities and is considered to be the prototype proinflammatory cytokine (1, 2). Mature canine IFN-gamma exists as a noncovalently linked homodimer of 20‑25 kDa variably glycosylated subunits (3). It shares 79‑88% amino acid sequence identity with bovine, equine, and feline IFN-gamma, 62‑73% with human, porcine, and rhesus IFN-gamma, and 40‑47% with cotton rat, mouse, and rat IFN-gamma. IFN-gamma dimers bind to IFN-gamma RI (alpha subunits) which then interact with IFN-gamma RII (beta subunits) to form the functional receptor complex of two alpha and two beta subunits. Inclusion of IFN-gamma RII increases the binding affinity for ligand and the efficiency of signal transduction (4, 5). IFN-gamma is produced by a variety of immune cells under inflammatory conditions, notably by T cells and NK cells (6). It plays a key role in host defense by promoting the development and activation of Th1 cells, chemoattraction and activation of monocytes and macrophages, up regulation of antigen presentation molecules, and immunoglobulin class switching in B cells. It also exhibits antiviral, antiproliferative, and apoptotic effects (6, 7). In addition, IFN-gamma functions as an anti-inflammatory mediator by promoting the development of regulatory T cells and inhibiting Th17 cell differentiation (8, 9). The pleiotropic effects of IFN-gamma contribute to the development of multiple aspects of atherosclerosis (7). |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 参考文献 |
|
IFN‑ gamma Inhibition of VSV-induced Cytopathy and Neutralization by Canine IFN‑ gamma Antibody. Recombinant Canine IFN‑ gamma (Catalog # 781-CG) reduces the Vesticular Stomatitis Virus (VSV)-induced cytopathy in the A‑72 canine fibroma cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Inhibition of VSV activity elicited by Recombinant Canine IFN‑ gamma (1.5 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Canine IFN‑ gamma Antigen Affinity-purified Polyclonal Antibody (Catalog # AF781). The ND50 is typically 0.2-1 µg/mL. | |
IFN‑ gamma in Canine PBMCs. IFN‑ gamma was detected in immersion fixed canine peripheral blood mononuclear cells (PBMCs) untreated (lower panel) or treated with PMA and calcium ionomycin (upper panel) using Goat Anti-Canine IFN‑ gamma Antigen Affinity-purified Polyclonal Antibody (Catalog # AF781) at 15 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI (blue). Specific staining was localized to cytoplasmic. View our protocol for Fluorescent ICC Staining of Non-adherent Cells. |
